LONDON, Sept 9 (Askume) – AstraZeneca (AZN.L) on Monday released detailed results from a major lung cancer trial, showing its experimental precision medicine had a significant impact on overall survival outcomes for patients in the trial.
The overall survival (OS) rate in the TROPION-LUNG01 trial “failed to reach statistical significance,” the company said in a presentation at the World Lung Cancer Conference in San Diego.
The final-stage trials are being closely watched by investors and analysts, who predict that the drug, called Datto-DXD, could become one of the company’s best-selling drugs.
The trial compared AstraZeneca’s drug to chemotherapy in patients whose non-small cell lung cancer had returned after one or two previous treatment attempts.
Previously released trial-related data has shaken stock prices. In July 2023, the stock price fell 8% after the pharmaceutical company released interim data on progression-free survival (PFS). Later this year, when the companyWhen more trial-related PFS data was released, the numbers dropped again.
Overall survival is another important efficacy parameter of anticancer drugs.
The drug, called Daito-DXD, belongs to a promising class of antibody-drug conjugates (ADCs) that consist of tumor-seeking monoclonal antibodies combined with a cell-killing chemotherapy payload. It was developed in partnership with Japan’s Daiichi Sankyo (4568.T) .
